Surface Ophthalmics develops patented eye drop formulations targeting dry eye syndrome, a condition affecting tear film stability and ocular surface health. Their pipeline includes both prescription and over-the-counter treatments designed to address the diverse etiologies and symptoms of this underdiagnosed disease.
Funding
$46.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Dry eye syndrome, characterized by tear film instability, hyperosmolarity, ocular surface inflammation, and neurosensory abnormalities, affects an estimated 38 million people, but remains underdiagnosed and undertreated. Current prescription therapies often see low renewal rates, indicating a need for more effective and diverse treatment options.
Solution
Surface Ophthalmics is developing a portfolio of patented, topical eye drop solutions, including both prescription (Rx) and over-the-counter (OTC) options, designed to address the diverse etiologies and symptoms of dry eye syndrome. Their treatments target the entire spectrum of dry eye, from episodic to chronic forms, as well as surgery-associated cases. By leveraging learnings from the current treatment landscape, Surface Ophthalmics aims to provide eye care professionals with a comprehensive suite of products tailored to individual patient needs, effectively addressing the signs, symptoms, and underlying causes of dry eye. The company has evaluated novel formulations in Phase II clinical trials involving over 550 patients across more than 50 U.S. clinical sites.
Target Audience
The primary target audience includes eye care professionals (ECPs) such as ophthalmologists and optometrists, as well as the 38 million people who suffer from dry eye syndrome.
Features
- Kera Sol TM Tears: Investigational treatment for dry eye syndrome.
- Mycosol (Surf-101): Investigational treatment for dry eye syndrome.
- Betasol (Surf-201): Investigational treatment for dry eye syndrome.
- Proprietary and patented portfolio leveraging learnings from the current treatment landscape.
- Treatments in development to address the entire range of dry eye syndrome, including episodic and chronic forms.